Drug
Fazirsiran
Fazirsiran: highest development phase Phase 3, developed by Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fazirsiran Injection NCT06165341 | Phase 3 | Alpha1-Antitrypsin Deficiency |
| Fazirsiran Injection NCT05899673 | Phase 3 | Alpha1-Antitrypsin Deficiency |
Latest
No recent events.
Follow Fazirsiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.